Dysregulation of antiviral function of CD81 T cells in the chronic obstructive pulmonary disease lung role of the PD-1-PD-L1 axis

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 6, 2016, Pages 642-651

  McKendry, Richard T ^a   Spalluto, C Mirella ^a   Burke, Hannah ^a   Nicholas, Ben ^a   Cellura, Doriana ^a   Al Shamkhani, Aymen ^a   Staples, Karl J ^a   Wilkinson, Tom M A ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Macrophage; PD 1; T cell; Viral infection

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DEGRANULATION; DISEASE EXACERBATION; EPITHELIUM CELL; EX VIVO STUDY; EXPLANT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INFLUENZA; LUNG RESECTION; LYMPHOCYTE FUNCTION; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; COMPLICATION; IMMUNOLOGY; LUNG; MIDDLE AGED; SIGNAL TRANSDUCTION;

AGED; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; INFLUENZA, HUMAN; LUNG; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84988719209     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201504-0782OC     Document Type: Article

References (39)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD [updated February 2014; accessed 2015 Nov 14]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf
3. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27: 188-207.
4. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285.
5. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(Suppl 2):5S-9S.
6. O?Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD81 T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-857.
7. Erickson JJ, Gilchuk P, Hastings AK, Tollefson SJ, Johnson M, Downing MB, Boyd KL, Johnson JE, Kim AS, Joyce S, et al. Viral acute lower respiratory infections impair CD81 T cells through PD-1. J Clin Invest 2012;122:2967-2982.
8. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068.
9. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007;19:309-314.
10. Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, Thanavala Y. T-regulatory cells and programmed death 11 T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;190:40-50.
11. Staples KJ, Nicholas B, McKendry RT, Spalluto CM, Wallington JC, Bragg CW, Robinson EC, Martin K, Djukanović R, Wilkinson TM. Viral infection of human lung macrophages increases PDL1 expression via IFNb. PLoS One 2015;10:e0121527.
12. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD81 T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-826.
13. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ, Kuchroo VK, Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107:14733-14738.
14. Nicholas B, Staples K, Moese S, Ward J, North M, Wilkinson T, Pink S, Djukanovic R. Validation of anti-host cell influenza targets using a novel human lung tissue model [abstract]. Am J Respir Crit Care Med 2012;185:A5716.
15. Nicholas B, Staples KJ, Moese S, Meldrum E, Ward J, Dennison P, Havelock T, Hinks TS, Amer K, Woo E, et al. A novel lung explant model for the ex vivo study of efficacy and mechanisms of anti-influenza drugs. J Immunol 2015;194:6144-6154.
16. Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978;273:238-239.
17. Topham DJ, Tripp RA, Doherty PC. CD81 T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997;159: 5197-5200.
18. Mueller SN, Langley WA, Carnero E, García-Sastre A, Ahmed R. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD81 T-cell responses. J Virol 2010;84:1847-1855.
19. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest 2008;134:46-53.
20. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
21. Knudson CJ, Weiss KA, Hartwig SM, Varga SM. The pulmonary localization of virus-specific T lymphocytes is governed by the tissue tropism of infection. J Virol 2014;88:9010-9016.
22. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS. Resident memory T cells (TRM) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 2011;6:e16245.
23. Freeman CM, McCubbrey AL, Crudgington S, Nelson J, Martinez FJ, Han MK, Washko GR Jr, Chensue SW, Arenberg DA, Meldrum CA, et al. Basal gene expression by lung CD41 T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. PLoS One 2014;9:e96421.
24. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-772.
25. Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, Tan Y, Wang S. PD-11 CD81 T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer 2014;111: 1391-1399.
26. Utzschneider DT, Legat A, Fuertes Marraco SA, CarriéL, Luescher I, Speiser DE, Zehn D. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 2013; 14:603-610.
27. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
28. McNally B, Ye F, Willette M, Flaño E. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J Virol 2013;87: 12916-12924.
29. Peters PJ, Borst J, Oorschot V, Fukuda M, Krä henbühl O, Tschopp J, Slot JW, Geuze HJ. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 1991;173:1099-1109.
30. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-499.
31. Fang M, Siciliano NA, Hersperger AR, Roscoe F, Hu A, Ma X, Shamsedeen AR, Eisenlohr LC, Sigal LJ. Perforin-dependent CD41 T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci USA 2012;109:9983-9988.
32. Jellison ER, Kim SK, Welsh RM. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005; 174:614-618.
33. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD41 T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18: 274-280.
34. Stanciu LA, Bellettato CM, Laza-Stanca V, Coyle AJ, Papi A, Johnston SL. Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines. J Infect Dis 2006;193: 404-412.
35. Telcian AG, Laza-Stanca V, Edwards MR, Harker JA, Wang H, Bartlett NW, Mallia P, Zdrenghea MT, Kebadze T, Coyle AJ, et al. RSVinduced bronchial epithelial cell PD-L1 expression inhibits CD81 T cell nonspecific antiviral activity. J Infect Dis 2011;203:85-94.
36. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-947.
37. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011;183:734-742.
38. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD81 T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
39. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.